TriSalus Life Sciences (TLSIW) Common Equity (2022 - 2025)
Historic Common Equity for TriSalus Life Sciences (TLSIW) over the last 4 years, with Q3 2025 value amounting to -$26.7 million.
- TriSalus Life Sciences' Common Equity fell 3078.69% to -$26.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$26.7 million, marking a year-over-year decrease of 3078.69%. This contributed to the annual value of -$25.9 million for FY2024, which is 432.66% up from last year.
- Per TriSalus Life Sciences' latest filing, its Common Equity stood at -$26.7 million for Q3 2025, which was down 3078.69% from -$19.4 million recorded in Q2 2025.
- TriSalus Life Sciences' Common Equity's 5-year high stood at $8.5 million during Q3 2023, with a 5-year trough of -$198.4 million in Q2 2023.
- Moreover, its 4-year median value for Common Equity was -$25.9 million (2024), whereas its average is -$53.4 million.
- Over the last 5 years, TriSalus Life Sciences' Common Equity had its largest YoY gain of 17279.25% in 2023, and its largest YoY loss of 161858.64% in 2023.
- TriSalus Life Sciences' Common Equity (Quarter) stood at -$176.3 million in 2022, then soared by 84.65% to -$27.1 million in 2023, then rose by 4.33% to -$25.9 million in 2024, then dropped by 3.21% to -$26.7 million in 2025.
- Its last three reported values are -$26.7 million in Q3 2025, -$19.4 million for Q2 2025, and -$34.4 million during Q1 2025.